Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

NCT ID: NCT04979130

Last Updated: 2025-03-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 69 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-01
• Study Completion Date: 2024-10-16

Brief Summary

This study plans to learn more about the effect of semaglutide once weekly on intestinal permeability in individuals with type 2 diabetes.

Conditions

Type 2 Diabetes; Chronic Inflammation; Intestinal Permeability

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

SC semaglutide

Participants receive a once weekly, subcutaneous, Semaglutide injection for 16 weeks in addition to the participants background metformin monotherapy. The participants in this arm will begin at a 0.25 mg dose during the randomization visit, at week 4 this will be escalated to a 0.5 mg dose and at week 8 it will be escalated again to a 1.0 mg dose if tolerable by the participant. If the participant cannot tolerate the 0.25 mg dose at randomization or the 0.5 mg dose at week 4 they will be withdrawn from the study.

Group Type: EXPERIMENTAL

Semaglutide

Intervention Type: DRUG

Semaglutide 1.34 mg/mL solution for injection in 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.

Placebo

Participants in this arm will be given a once weekly, subcutaneous, placebo injection matching the Semaglutide experimental arm in addition to their background metformin monotherapy.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.

Interventions

Semaglutide

Semaglutide 1.34 mg/mL solution for injection in 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.

Intervention Type: DRUG

Placebo

Semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.

Intervention Type: DRUG

Other Intervention Names

Ozempic; PDS290 pen-injector; PDS290 pen-injector

Eligibility Criteria

Inclusion Criteria

1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial, except for protocol described pre-screening activities, which require a separate informed consent.

2. Male or female, age above or equal to 18 years at the time of signing informed consent.

3. Diagnosed with type 2 diabetes mellitus on metformin monotherapy

4. Hemoglobin A1c <8.0% (<64 mmol/mol) on screening day

5. Body mass index (BMI) ≥28 kg/m2

6. Low-grade inflammation, defined as elevated high sensitivity C-reactive protein (hs- CRP >1.0 and ≤10 mg/L). Impaired intestinal barrier function results in activation of inflammatory pathway; therefore, excluding subjects with no evidence of inflammation (hs-CRP ≤ 1 mg/L) will help to enrich our study population. Similar threshold for hs-CRP as a marker of "residual inflammatory risk" (29) has been previously used as an independent predictor of future vascular events (26, 30).

Exclusion Criteria

1. Known or suspected hypersensitivity to trial product or related products.

2. Female who is pregnant, breast-feeding or intends to become pregnant or is of child- bearing potential and not using a highly effective contraceptive method.

3. Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days before screening.

4. Any disorder, which in the investigator's opinion might jeopardize patient's safety or compliance with the protocol.

5. Any of the following: myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischemic attack (TIA) within the past 60 days prior to the day of screening.

6. Second anti-diabetic agent use within 3 months of screening.

7. Chronic kidney disease defined as eGFR < 30 mL/min/1.73 m2.

8. C-reactive protein (hs-CRP >10.0 mg/L) to eliminate patients with acute inflammatory process at the time of screening.

9. Any recent infection or antibiotic use within 3 weeks

10. Regular use (more than a week duration) of anti-inflammatory medication (steroid or NSAIDs) within 3 months of screening.

11. Regular use (more than a week duration) of any digestive health supplements, such as probiotics or prebiotics within 3 months screening.

12. Diagnosis of chronic intestinal inflammatory disease such as Crohn's disease, ulcerative colitis or irritable bowel syndrome.

13. Prior bariatric or bowel surgery

14. Heart failure presently classified as being in New York Heart Association (NYHA) Class IV.

15. Presence or history of malignant neoplasm within 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ is allowed.

16. Personal or family history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC).

17. History of chronic pancreatitis or history of acute pancreatitis within 6 months of screening.

18. Chronic consumption of > 2 alcoholic standard drinks per day as defined by:

• 12 ounces of beer (5% alcohol content).
• 8 ounces of malt liquor (7% alcohol content).
• 5 ounces of wine (12% alcohol content).
• 1.5 ounces or a "shot" of 80-proof (40% alcohol content) distilled spirits or liquor (e.g., gin, rum, vodka, whiskey).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 89 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novo Nordisk A/S

INDUSTRY

Sponsor Role: collaborator

University of Colorado, Denver

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Neda Rasouli, MD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Joseph Onyiah, MD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Locations

University of Colorado Anschutz

Aurora, Colorado, United States

Countries

United States

Other Identifiers

21-2774

Identifier Type: -

Identifier Source: org_study_id